Digital PCR detection method and application of human PIK3CA gene mutation

Through the combination of digital PCR platform and specific primer probes, the problem of insufficient sensitivity and specificity of PIK3CA gene mutation detection in the prior art is solved, and high sensitivity and high specificity detection of PIK3CA gene mutations is achieved, which is suitable for complex Sample, simplifying the detection process.

CN113930500BActive Publication Date: 2024-11-19MINGCHI BIOTECHNOLOGY (SHANGHAI) CO LTD +1
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202010670563.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2020-07-13
Publication Date
2024-11-19
Estimated Expiration
2040-07-13

AI Technical Summary

Technical Problem

In the prior art, when detecting PIK3CA gene mutations, especially when using cfDNA in plasma as a sample, the sensitivity and specificity are insufficient, resulting in inaccurate detection results, especially in the case of uneven quality and low content of free nucleic acids from tumor-derived sources. Under the slightest, it is difficult to meet clinical needs.

Method used

The digital PCR platform is used to combine specific primers and probe design to detect PIK3CA E545, E542 and H1047 sites. By optimizing the primer sequence and probe structure, the sensitivity and specificity of the detection are improved. The designed primer pairs and probes can be used to Wild-type and mutant templates at target sites are specifically amplified, using locking nucleotide modification to enhance binding, a combination of fluorescent groups and quenching groups to improve detection signal discrimination ability.

Benefits of technology

It realizes high sensitivity and specificity detection of PIK3CA gene mutations, and can accurately identify mutations in low concentrations and complex samples, with a sensitivity of 0.06%. It is suitable for samples of different difficulties, including peripheral blood samples, with strong anti-interference ability and simplified Positive interpretation method.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002582128020000151
    Figure BDA0002582128020000151
  • Figure BDA0002582128020000161
    Figure BDA0002582128020000161
  • Figure BDA0002582128020000171
    Figure BDA0002582128020000171
Patent Text Reader

Abstract

The present invention provides a digital PCR detection method and application of human PIK3CA gene mutation. Specifically, preferred primer pairs, amplification methods, nucleic acid probes and detection systems for the sequences of PIK3CA E545, E542 and PIK3CA H1047 are provided, and a kit for detecting PIK3CA gene mutation is further provided. The present invention can detect PIK3CA gene mutation with high sensitivity and strong specificity for different samples through optimized primer pairs and probes and corresponding reaction conditions.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of gene detection, and in particular to a digital PCR detection method and application of human PIK3CA gene mutation. Background Art

[0002] PIK3CA is a proto-oncogene located on chromosome 3, with a total of 20 exons. About 80% of PIK3CA mutations occur in the two hotspots of the helical region and the kinase region, of which the three most common mutations are H1047R on exon 20, E542K and E545K on exon 9. Mutations in the PIK3CA gene can not only increase the catalytic activity of PI3Ks, but also promote cell carcinogenesis.

[0003] PI3Ks, as downstream signaling molecules of EGFR, are activated and can lead to resistance of tumor cells to EGFR-TKI drugs. For example, mutations in the PIK3CA gene can lead to resistance to the treatment of metastatic colorectal cancer with cetuximab and panitumumab, and resistance to the treatment of non-small cell lung cancer with gefitinib and erlotinib. PIK3CA mutations are ineffective for the treatment of trastuzumab, a personalized targeted drug for breast cancer, while wild-type treatment is effective. Any one or more mutations in KRAS, BRAF, and PIK3CA are ineffective for the treatment of personalized targeted drugs for colorectal cancer with cetuximab and panitumumab, while all wild-type treatments are effective.

[0004] Therefore, the detection of PIK3CA gene mutation can provide a reference for doctors to select targeted drugs such as gefitinib, erlotinib and icotinib for patients with non-small cell lung cancer; provide a reference for the use of targeted drugs such as cetuximab and panitumumab for patients with colorectal cancer; and provide a reference for the selection of targeted drugs such as trastuzumab for patients with breast cancer.

[0005] However, in the actual process of detecting PIK3CA gene mutations in patients with colorectal cancer, there are still problems such as the quality of test samples. Although tumor tissue and tumor cytology samples are the best samples for mutation detection, such samples are difficult to obtain. Detecting free nucleic acids (circulating free DNA, referred to as "cfDNA") in plasma, also known as "liquid biopsy", avoids the need for tumor tissue biopsy and is a very useful diagnostic application in clinical practice. The use of liquid biopsy provides the possibility of repeated blood sampling, allowing the tracking of changes in cfDNA during tumor development or during cancer treatment, thereby monitoring changes in the disease.

[0006] However, it is difficult to use cell-free nucleic acids (such as cfDNA) as biomarkers in cancer patients, especially the use of cfDNA to accurately and specifically detect gene mutations. First, the amount of cfDNA in the blood varies from person to person, and in most cases it is very low. The quality of circulating tumor DNA (ctDNA) from tumors is even more uneven, and the content varies.

[0007] Moreover, the specificity of cfDNA detection needs to be improved. Douillard et al. reported that the consistency between the detection of EGFR mutations in plasma and the detection results in tumor tissue was only 65%.

[0008] In addition, although there are some methods based on cfDNA to detect PIK3CA gene mutations, the sensitivity and specificity of these methods are still far from satisfactory.

[0009] Therefore, there is an urgent need to develop a method for detecting PIK3CA gene mutations with high sensitivity and specificity based on cfDNA. Summary of the invention

[0010] The object of the present invention is to provide a method for detecting PIK3CA gene mutations with high sensitivity and high specificity based on cfDNA.

[0011] In a first aspect of the present invention, a reagent for detecting gene mutation is provided, wherein the reagent is selected from the following group:

[0012] (a) a first primer pair for detecting PIK3CA E545 and / or E542 mutations, wherein the first primer pair comprises primers shown in SEQ ID Nos: 1 and 2;

[0013] (b) a second primer pair for detecting PIK3CA H1047 mutation, wherein the second primer pair comprises primers shown in SEQ ID No: 7 and 8;

[0014] (c) A combination of (a) and (b) above.

[0015] In another preferred embodiment, the sequences of PIK3CA E545 and E542 are located at NG_012113.2:74725-74820.

[0016] In another preferred embodiment, the sequence of PIK3CA H1047 is located at NG_012113.2:90725-90819.

[0017] In another preferred example, the nucleic acid sequence of the wild-type sequence of PIK3CA E545 / E542 is shown in SEQ ID NO.:11.

[0018] In another preferred embodiment, the mutations are PIK3CA E545K, E542K, and H1047R.

[0019] In another preferred example, the nucleic acid sequence of the wild-type sequence of PIK3CA H1047 is shown in SEQ ID NO.:14.

[0020] In another preferred embodiment, the PIK3CA E545K mutation refers to the mutation of glutamic acid E at position 545 of the amino acid sequence of the PIK3CA protein to lysine K (ie, E545K).

[0021] In another preferred embodiment, the PIK3CA E542K mutation refers to the mutation of glutamic acid E at position 542 of the amino acid sequence of the PIK3CA protein to lysine K (ie, E542K).

[0022] In another preferred embodiment, the PIK3CA H1047R mutation refers to the mutation of histidine H at position 1047 in the amino acid sequence of the PIK3CA protein to arginine R (ie, H1047R).

[0023] In another preferred embodiment, the PIK3CA E545K mutation refers to the mutation of guanine G at position 1633 of the PIK3CA gene nucleic acid sequence to adenine A (PIK3CA c.1633G>A).

[0024] In another preferred embodiment, the PIK3CA E542K mutation refers to the mutation of guanine G at position 1624 of the PIK3CA gene nucleic acid sequence to adenine A (PIK3CA c.1624G>A).

[0025] In another preferred embodiment, the PIK3CA H1047R mutation refers to the mutation of adenine A at position 3140 of the PIK3CA gene nucleic acid sequence to guanine G (PIK3CA c.3140A>G).

[0026] In another preferred example, the PIK3CA E545K mutant nucleic acid sequence is shown in SEQ ID NO:12.

[0027] In another preferred example, the PIK3CA E542K mutant nucleic acid sequence is shown as SEQ ID NO.:13.

[0028] In another preferred example, the PIK3CA H1047R mutant nucleic acid sequence is shown in SEQ ID NO.:15.

[0029] In another preferred embodiment, the reagent further comprises:

[0030] (a1) A first probe used in conjunction with the first primer pair, wherein the first probe is selected from the group consisting of a probe shown in SEQ ID No: 3, a probe shown in SEQ ID No: 4, a probe shown in SEQ ID No: 5, a probe shown in SEQ ID No: 6, or a combination thereof.

[0031] In another preferred embodiment, the reagent further comprises:

[0032] (b1) A second probe used in conjunction with the second primer pair, wherein the second probe is selected from the group consisting of a probe shown in SEQ ID No: 9, a probe shown in SEQ ID No: 10, or a combination thereof.

[0033] In another preferred embodiment, the first probe and the second probe are single-stranded nucleic acid probes.

[0034] In another preferred embodiment, the nucleic acid probe contains one or more locked nucleotides.

[0035] In another preferred embodiment, the structure (5'-3') of the first probe is as shown in Formula I:

[0036] Z1-Z2-Z3 I

[0037] in,

[0038] Z1 is a fluorescent group;

[0039] Z2 is a specific complementary nucleic acid sequence;

[0040] Z3 is a quenching group;

[0041] “-” is a chemical bond, a linker, or a linker consisting of 1-3 nucleotides.

[0042] In another preferred embodiment, the Z2-specific nucleic acid sequence targets the wild-type PIK3CA E545 and E542 sites.

[0043] In another preferred embodiment, the Z2-specific nucleic acid sequence targets the mutant PIK3CA E545K site.

[0044] In another preferred embodiment, the Z2-specific nucleic acid sequence targets the mutant PIK3CA E542K site.

[0045] In another preferred embodiment, the Z2 contains a locked nucleotide modification.

[0046] In another preferred embodiment, the sequence of Z2 is selected from the following group:

[0047] TCTCCTGCTCAGTGA(SEQ ID No:3);

[0048] TCTCCTGCTTAGTGA(SEQ ID No:4);

[0049] CGAGATCCTTCTCTGAA(SEQ ID No:5);

[0050] CGAGATCCTCTCTCTAAAA (SEQ ID No: 5).

[0051] In another preferred embodiment, the fluorescent groups are independently located at the 5' end, 3' end and the middle of the nucleic acid probe.

[0052] In another preferred embodiment, the fluorescent group and the quencher group are independently located at the 5' end, the 3' end, and / or the middle.

[0053] In another preferred embodiment, the fluorescent group includes a fluorescent group cross-linked with a DNA probe.

[0054] In another preferred embodiment, the fluorescent group is selected from the following group: FAM, VIC, HEX, FITC, BODIPY-FL, G-Dye100, FluorX, Cy3, Cy5, Texas Red, or a combination thereof.

[0055] In another preferred embodiment, the quenching group is selected from the following group: DABCYL, TAMRA, BHQ 1, BHQ 2, BHQ3, MGB, NFQ, BBQ-650, TQ1-TQ6, QSY 7carboxyl ic acid, TQ7, eclipse, or a combination thereof.

[0056] In another preferred embodiment, the nucleic acid probe is WTP-PIK3CA E545 (SEQ ID No: 3).

[0057] In another preferred embodiment, the nucleic acid probe is WTP-PIK3CA E545K (SEQ ID No: 4).

[0058] In another preferred embodiment, the nucleic acid probe is MTP-PIK3CA E542 (SEQ ID No: 5).

[0059] In another preferred embodiment, the nucleic acid probe is WTP-PIK3CA E542K (SEQ ID No: 6).

[0060] In another preferred embodiment, the structure (5'-3') of the second probe is as shown in Formula II:

[0061] Z1'-Z2'-Z3' II

[0062] in,

[0063] Z1' is a fluorescent group;

[0064] Z2' is a specific complementary nucleic acid sequence;

[0065] Z3' is a quenching group;

[0066] “-” is a chemical bond, a linker, or a linker consisting of 1-3 nucleotides.

[0067] In another preferred embodiment, the Z2'-specific nucleic acid sequence targets the wild-type PIK3CA H1047 site.

[0068] In another preferred embodiment, the Z2'-specific nucleic acid sequence targets the mutant PIK3CA H1047R site.

[0069] In another preferred embodiment, the sequence of Z2' is selected from the following group:

[0070] CACCATGATGTGCATCA(SEQ ID No:9);

[0071] CACCATGACGTGCATC (SEQ ID No: 10).

[0072] In another preferred embodiment, the nucleic acid probe is WTP-PIK3CA H1047 (SEQ ID No: 9).

[0073] In another preferred embodiment, the nucleic acid probe is MTP-PIK3CA H1047R (SEQ ID No: 10).

[0074] In a second aspect of the present invention, a kit is provided, wherein the kit contains the reagent for detecting gene mutations described in the first aspect.

[0075] In another preferred embodiment, the kit further comprises a first probe used in conjunction with the first primer pair; and / or a second probe used in conjunction with the second primer pair.

[0076] In another preferred example, the first primer pair, the second primer pair, the first probe, and the second probe are as described above.

[0077] In another preferred embodiment, the kit includes a first primer pair shown in SEQ ID Nos: 1 and 2, and a first probe shown in SEQ ID Nos: 3, 4, 5 and 6.

[0078] In another preferred embodiment, the kit includes a second primer pair shown in SEQ ID Nos: 7 and 8, and a second probe shown in SEQ ID Nos: 9 and 10.

[0079] In the third aspect of the present invention, there is provided a use of the reagent for detecting gene mutation as described in the first aspect or the kit as described in the second aspect, for preparing a diagnostic product, wherein the diagnostic product is used to judge whether a subject is suitable for treatment with EGFR targeted drugs, or to pre-evaluate the effect of EGFR targeted drugs on a subject.

[0080] In another preferred embodiment, the EGFR targeted drug is selected from the following group: fetinib, erlotinib, icotinib, cetuximab, panitumumab, or a combination thereof.

[0081] In another preferred embodiment, the product is used to detect cfDNA samples.

[0082] In another preferred embodiment, the cfDNA is from the blood, plasma, or serum of the subject.

[0083] In another preferred embodiment, the subject is a tumor patient and / or a leukemia patient.

[0084] In another preferred embodiment, the tumor is an EGFR-positive tumor.

[0085] In another preferred embodiment, the tumor is selected from the following group: colon cancer, liver cancer, lung cancer, gastric cancer, breast cancer, or a combination thereof.

[0086] In a fourth aspect of the present invention, a method for detecting whether a sample to be tested contains a gene mutation is provided, comprising the steps of:

[0087] (S1) providing a PCR reaction system, wherein the PCR reaction system contains a sample to be tested as a template and a primer pair for amplification, wherein the primer pair is selected from the following group:

[0088] (a) a first primer pair for detecting PIK3CA E545 and / or E542 mutations, wherein the first primer pair comprises primers shown in SEQ ID Nos: 1 and 2;

[0089] (b) a second primer pair for detecting PIK3CA H1047 mutation, wherein the second primer pair comprises primers shown in SEQ ID No: 7 and 8;

[0090] (c) a combination of (a) and (b) above;

[0091] The reagent for detecting gene mutation according to the first aspect;

[0092] (S2) performing a PCR reaction on the PCR reaction system of step (S1) to obtain an amplified product;

[0093] (S3) Analyzing the amplification product produced in step (S2) to obtain an analysis result of whether the sample to be tested contains a gene mutation.

[0094] In another preferred embodiment, the analysis result is a qualitative result.

[0095] In another preferred embodiment, the PCR reaction system is a digital PCR reaction system.

[0096] In another preferred embodiment, the digital PCR is ddPCR.

[0097] In another preferred embodiment, the concentration of the target nucleic acid molecule to be detected in the ddPCR in the droplet is 1 to 1×10 15 Copies / ml, preferably 1 to 10 10 copies / ml, preferably 1 to 10 5 copies / ml.

[0098] In another preferred embodiment, in step (S2), the annealing temperature of the PCR reaction is 56±2°C, preferably 56±1°C, and more preferably 56±0.5°C.

[0099] In another preferred embodiment, the PCR reaction system further comprises:

[0100] (a1) a first probe used in conjunction with the first primer pair, wherein the first probe is selected from the group consisting of a probe shown in SEQ ID No: 3, a probe shown in SEQ ID No: 4, a probe shown in SEQ ID No: 5, a probe shown in SEQ ID No: 6, or a combination thereof; and / or

[0101] (b1) A second probe used in conjunction with the second primer pair, wherein the second probe is selected from the group consisting of a probe shown in SEQ ID No: 9, a probe shown in SEQ ID No: 10, or a combination thereof.

[0102] In another preferred embodiment, the probes for detecting the wild-type gene (SEQ ID No: 3, SEQ ID No: 5 and SEQ ID No: 9) use the same first fluorescent marker (such as HEX, FAM).

[0103] In another preferred embodiment, the probes for detecting mutant genes (SEQ ID No: 4, 6 and 10) use the same second fluorescent marker (such as HEX, FAM), and the first fluorescent marker and the second fluorescent marker are different.

[0104] In another preferred embodiment, the method is non-diagnostic and non-therapeutic.

[0105] In another preferred embodiment, the method is an in vitro method.

[0106] In another preferred example, the detection accuracy of the method is 0.06%-1%, preferably 0.0625%-0.08%.

[0107] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0108] Figure 1 Shows the results of PCR electrophoresis of 5 pairs of primers for PIK3CA E545 and E542 (M: DNA Marker)

[0109] Figure 2 Shows the results of PCR electrophoresis of 5 pairs of primers for PIK3CA H1047 (M: DNA Marker)

[0110] Figure 3 The annealing temperature optimization of the Taqman-ddPCR method for detecting the E545K mutation of the PIK3CA gene is shown. Wells B\D\F\H represent the annealing temperature gradient of 60°C, 58°C, 56°C, and 54°C. A is a 1-D amplitude graph of the positive control (100% E545K mutation) detected by the FAM channel; B is a 1-D amplitude graph of the negative control detected by the HEX channel

[0111] Figure 4 :Shows the optimization of annealing temperature for the Taqman-ddPCR method for detecting the E542K mutation of the PIK3CA gene. Wells A\C\E\G represent the annealing temperature gradient of 60℃, 58℃, 56℃, and 54℃. A is a 1-D amplitude graph of the positive control detected by the FAM channel; B is a 1-D amplitude graph of the positive control detected by the HEX channel.

[0112] Figure 5The annealing temperature optimization of the Taqman-ddPCR method for detecting the H1047R mutation of the PIK3CA gene is shown. The wells A\C\E\G represent the annealing temperature gradient of 60°C, 58°C, 56°C, and 54°C. A is a 1-D amplitude graph of the positive control detected by the FAM channel; B is a 1-D amplitude graph of the positive control detected by the HEX channel.

[0113] Figure 6 The figure shows the validation of the detection concentration of PIK3CA E545K gene mutation. As can be seen from the figure, the linearity of this detection method is very good within all detection concentrations (0.06%-1%), that is, the sensitivity of this method reaches 0.06%

[0114] Figure 7 The figure shows the validation of the detection concentration of PIK3CA E542K gene mutation. As can be seen from the figure, the linearity of this detection method is very good within all detection concentrations (0.06%-1%), that is, the sensitivity of this method reaches 0.06%.

[0115] Figure 8 The figure shows the validation of the detection concentration of PIK3CA H1047R gene mutation. As can be seen from the figure, the linearity of this detection method is very good within all detection concentrations (0.06%-1%), that is, the sensitivity of this method reaches 0.06%.

[0116] Fig. 9 The case "MS1106" was negative for PIK3CA by digital PCR. From top to bottom, the two-dimensional detection graphs of E545K, E542K, and H1047R (2D amplitude graph of the FAM-HEX channel) are shown. The green one is the wild-type signal.

[0117] Fig.10 The two-dimensional graph (2D graph of FAM-HEX channel) of the case "MS1124" by digital PCR detection of PIK3CA E545K is shown. The blue and orange are mutation signals, indicating that the case "MS1124" is PIK3CAE545K positive by digital PCR.

[0118] Fig.11 The two-dimensional image (2D image of FAM-HEX channel) of the case "MS1133" detected PIK3CA E542K by digital PCR is shown. The blue and orange are mutation signals, indicating that the digital PCR detection is PIK3CA E542K positive.

[0119] Fig.12The two-dimensional image (2D image of FAM-HEX channel) of the case "MS1127" detected by digital PCR for PIK3CA H1047R is shown. The blue and orange colors are mutation signals, indicating that the digital PCR detection is positive for PIK3CA H1047R. DETAILED DESCRIPTION

[0120] After extensive and in-depth research, the inventors have found that through a large number of screenings, especially through the optimization of primer sequences and probes, combined with a digital PCR platform, the effect of gene mutation detection can be effectively improved, and the problems of using pathological tissue as starting material, low accuracy, low sensitivity, etc. in existing gene mutation detection technology have been broken through, and a method for detecting PIK3CA gene mutations with high specificity, high sensitivity, and strong anti-interference ability has been provided. On this basis, the inventors have completed the present invention.

[0121] Specifically, the present invention provides a detection method for PIK3CA E545K, PIK3CA E542K and PIK3CA H1047R mutant genes, that is, by providing two pairs of specially optimized primers for the sequences of PIK3CA E545 / E542 and PIK3CA H1047 and specially optimized probes for PIK3CA E545K, PIK3CA E542K, PIK3CA H1047R mutant genes, a digital PCR detection system is established, thereby qualitatively and quantitatively detecting the mutation of the PIK3CA gene. When the method and reagent of the present invention are used to detect PIK3CA gene mutations, they have unexpectedly high sensitivity and high specificity, and can detect samples of different difficulty levels.

[0122] the term

[0123] In order to more easily understand the present disclosure, some terms are first defined. As used in this application, unless otherwise expressly provided herein, each of the following terms should have the meaning given below. Other definitions are set forth throughout the application.

[0124] The term "about" can refer to a value or composition that is within an acceptable error range for a particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined. For example, as used herein, the expression "about 100" includes all values ​​between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).

[0125] As used herein, the term "comprising" or "including (comprising)" may be open, semi-closed and closed. In other words, the term also includes "consisting essentially of" or "consisting of".

[0126] Sequence identity is determined by comparing two aligned sequences along a predetermined comparison window (which can be 50%, 60%, 70%, 80%, 90%, 95% or 100% of the length of the reference nucleotide sequence or protein) and determining the number of positions at which identical residues occur. Typically, this is expressed as a percentage. The measurement of sequence identity of nucleotide sequences is a method well known to those skilled in the art.

[0127] Digital PCR technology

[0128] Digital PCR technology is an absolute quantitative method for nucleic acid quantification based on the single-molecule PCR method. It mainly uses the microfluidics or droplet method in the current hot research field of analytical chemistry to disperse a large amount of diluted nucleic acid solution into the microreactor or droplets of the chip, and the number of nucleic acid templates in each reactor is less than or equal to 1. After the PCR cycle, the fluorescence signal of each droplet is analyzed after the amplification is completed. The reactor with the nucleic acid molecule template will give a fluorescent signal, and the reactor without the template will not have a fluorescent signal. According to the relative proportion and the volume of the reactor, the nucleic acid concentration of the original solution can be calculated.

[0129] Compared with conventional qPCR, digital PCR can accurately quantify and detect target nucleic acid molecules with high sensitivity. The method for analyzing the results of conventional qPCR is an analog method, wherein the digital PCR method, the results of which are analyzed by a digital method (because the obtained signal has a value of "0" or "1"), has the advantages of being able to analyze large volume samples, simultaneously detect different samples, and simultaneously perform different tests. Digital PCR technology is a technology that can use a single molecule counting method without a standard curve to absolutely quantify DNA samples, and can perform more accurate absolute quantification of a single droplet per well by PCR (see Gudrun Pohl and le-Ming Shih, Principle and applications of digital PCR, Expert Rev. Mol. Diagn. 4 (1), 41-47 (2004)). Digital PCR has the advantages of high sensitivity, accurate quantification without a standard curve, and simple operation.

[0130] In digital PCR, each droplet containing a sample gene template prepared so as to be diluted to an average copy number of 0.5-1, amplification primers, and a fluorescent probe is dispensed into a single well, and microemulsion PCR is performed. Then, the wells showing a fluorescent signal are counted as a value of "1" because a sample with a gene copy number of 1 is dispensed into the well and shows a fluorescent signal after amplification, while the wells showing no signal are counted as "0" because a sample with a gene copy number of 0 is dispensed into the well and does not show a fluorescent signal due to no amplification. In this way, absolute quantification can be achieved.

[0131] Primers

[0132] Primer refers to a macromolecule with a specific nucleotide sequence that is stimulated to synthesize at the beginning of nucleotide polymerization and is covalently linked to the reactant. Primers are usually two artificially synthesized oligonucleotide sequences, one primer is complementary to a DNA template strand at one end of the target region, and the other primer is complementary to another DNA template strand at the other end of the target region.

[0133] In the present invention, in order to improve the sensitivity of the detection system, the corresponding gene fragment in the detection system is pre-amplified, and thus primers corresponding to the sequence where the mutation is located are designed.

[0134] In a preferred example, multiple pairs of primers were designed upstream and downstream of the E545 / E542 site of the PIK3CA gene for the sequence where PIK3CA E545 / E542 is located. After experimental testing, the optimal primer pair was finally determined to be SEQ ID No: 1 and 2.

[0135] In another preferred example, for the sequence where PIK3CA H1047 is located, multiple pairs of primers are designed upstream and downstream of the H1047 site of the PIK3CA gene. After experimental testing, the optimal primer pair is finally determined to be SEQ ID No: 3 and 4.

[0136] Probe

[0137] In this article, "probe", "nucleic acid probe" and "gene probe" are interchangeable and refer to a nucleic acid sequence (DNA or RNA) with a detection label and a known sequence that is complementary to the target gene. The gene probe binds to the target gene through molecular hybridization to generate a hybridization signal, which can display the target gene from the vast genome. According to the hybridization principle, the nucleic acid sequence used as a probe must meet at least the following two conditions: ① It should be single-stranded. If it is double-stranded, it must be denatured first; ② It should have a label that is easily detected. The nucleic acid probe can include the entire gene or only a part of the gene; it can be DNA itself or RNA transcribed from it. In the present invention, the probe also refers to a modified primer, which has chemical modification groups at both ends or in the middle. These chemical modifications have special functions including but not limited to: signal indication, enhanced connection with reactants, etc.

[0138] The structure of the first probe of the present invention is shown in Formula I:

[0139] Z1-Z2-Z3 I

[0140] in,

[0141] Z1 is a fluorescent group;

[0142] Z2 is a specific complementary nucleic acid sequence;

[0143] Z3 is a quenching group;

[0144] “-” is a chemical bond, a linker, or a linker consisting of 1-3 nucleotides.

[0145] In another preferred embodiment, the Z2-specific nucleic acid sequence targets the wild-type PIK3CA E545 and E542 sites.

[0146] In another preferred embodiment, the Z2-specific nucleic acid sequence targets the mutant PIK3CA E545K site.

[0147] In another preferred embodiment, the Z2-specific nucleic acid sequence targets the mutant PIK3CA E542K site.

[0148] In another preferred embodiment, the Z2 contains a locked nucleotide modification.

[0149] In another preferred embodiment, the sequence of Z2 is selected from the following group:

[0150] TCTCCTGCTCAGTGA(SEQ ID No:3);

[0151] TCTCCTGCTTAGTGA(SEQ ID No:4);

[0152] CGAGATCCTTCTCTGAA(SEQ ID No:5);

[0153] CGAGATCCTCTCTCTAAAA (SEQ ID No: 5).

[0154] In another preferred embodiment, the fluorescent groups are independently located at the 5' end, 3' end and the middle of the nucleic acid probe.

[0155] In another preferred embodiment, the fluorescent group and the quencher group are independently located at the 5' end, the 3' end, and / or the middle.

[0156] In another preferred embodiment, the fluorescent group includes a fluorescent group cross-linked with a DNA probe.

[0157] In another preferred embodiment, the fluorescent group is selected from the following group: FAM, VIC, HEX, FITC, BODIPY-FL, G-Dye100, FluorX, Cy3, Cy5, Texas Red, or a combination thereof.

[0158] In another preferred embodiment, the quenching group is selected from the following group: DABCYL, TAMRA, BHQ 1, BHQ 2, BHQ3, MGB, NFQ, BBQ-650, TQ1-TQ6, QSY 7carboxylic acid, TQ7, eclipse, or a combination thereof.

[0159] In another preferred embodiment, the nucleic acid probe is WTP-PIK3CA E545 (SEQ ID No: 3).

[0160] In another preferred embodiment, the nucleic acid probe is WTP-PIK3CA E545K (SEQ ID No: 4).

[0161] In another preferred embodiment, the nucleic acid probe is MTP-PIK3CA E542 (SEQ ID No: 5).

[0162] In another preferred embodiment, the nucleic acid probe is WTP-PIK3CA E542K (SEQ ID No: 6).

[0163] The structure (5'-3') of the second probe of the present invention is shown in Formula II:

[0164] Z1'-Z2'-Z3' II

[0165] in,

[0166] Z1' is a fluorescent group;

[0167] Z2' is a specific complementary nucleic acid sequence;

[0168] Z3' is a quenching group;

[0169] “-” is a chemical bond, a linker, or a linker consisting of 1-3 nucleotides.

[0170] In another preferred embodiment, the Z2'-specific nucleic acid sequence targets the wild-type PIK3CA H1047 site.

[0171] In another preferred embodiment, the Z2'-specific nucleic acid sequence targets the mutant PIK3CA H1047R site.

[0172] In another preferred embodiment, the sequence of Z2' is selected from the following group:

[0173] CACCATGATGTGCATCA(SEQ ID No:9);

[0174] CACCATGACGTGCATC (SEQ ID No: 10).

[0175] In another preferred embodiment, the nucleic acid probe is WTP-PIK3CA H1047 (SEQ ID No: 9).

[0176] In another preferred embodiment, the nucleic acid probe is MTP-PIK3CA H1047R (SEQ ID No: 10).

[0177] Modification of primers and probes

[0178] In the present invention, the nucleic acid sequence of the primer includes an unmodified or modified primer sequence.

[0179] Preferably, the inventors can significantly improve the specificity of the probe by modifying the probe with locked nucleotides, thereby improving the sensitivity and specificity of the detection results.

[0180] In a preferred example of the present invention, the modification method is selected from: phosphorylation, biotin, digoxigenin, internal amino modification, 5' amino modification, 3' amino modification, thiol, spacer, phosphorthioate, deoxyuridine (dU), deoxyinosine (dI), or a combination thereof.

[0181] Phosphorylation modification: 5' phosphorylation can be used for linkers, cloning and gene construction, as well as ligation reactions catalyzed by ligase. 3' phosphorylation can resist 3' exonuclease digestion in related experiments and is also used to prevent DNA polymerase-catalyzed DNA chain extension reactions.

[0182] Biotin modification: Primer biotin labeling can be used for non-radioactive immunoassay to detect proteins, intracellular chemical staining, cell separation, nucleic acid separation, hybridization detection of specific DNA / RNA sequences, ion channel conformational changes, etc.

[0183] Digoxin modification: Digoxin is linked to the C5 position of uracil via an 11-atom spacer, and the hybridized Digoxin probe can be detected by anti-Digoxin antibodies. Digoxin-labeled probes can be used in various hybridization reactions, such as DNA-DNA hybridization (Southern blotting), DNA-RNA hybridization (Northern blotting), dot hybridization (Dotblotting), clonal hybridization, in situ hybridization, and enzyme-linked immunosorbent assay (ELISA).

[0184] Internal amino modification: C6-dT aminolinker is mainly used to add to thymine residues for internal modification. After modification, the amino group is 10 atoms away from the main chain and can be used for further labeling and enzyme connection (such as alkaline phosphatase). Currently, dT-Dabcyl, dT-Biotin and dT-Digoxingenin modifications mediated by internal amino modification are provided.

[0185] 5' amino modification: can be used to prepare functionalized oligonucleotides, and is widely used in DNA chips (DNA Microarray) and multiple labeling diagnostic systems. Currently, 5'C6 amino modification and 5'C12 amino modification are available. The former can be used to connect some compounds that will not affect the function of oligonucleotides even if they are close to them, and the latter is used for the connection of affinity purification groups and some fluorescent labels, especially when the fluorescence may be quenched due to the label being too close to the DNA chain.

[0186] 3' amino modification: Currently, 3'C6 amino modification is available. It can be used to design new diagnostic probes and antisense nucleotides. For example, the 5' end can be labeled with highly sensitive 32P or fluorescein while the 3' end can be modified with amino for other connections. In addition, the 3' modification can inhibit 3' exonuclease digestion, so it can be used in antisense experiments.

[0187] Thiol modification: 5'-thiol modification is similar to amino modification in many ways. Thiols can be used to attach various modifications such as fluorescent markers and biotin. For example, thiol-linked fluorescent probes can be made in the presence of iodoacetic acid and maleimide derivatives. 5' thiol modification is mainly done with 5' thiol-modified monomers (5'-Thiol-Modifier C6-CE Phosphoramidite or Thiol-Modifier C6 SS CE Phosphoramidite). After modification with 5'-Thiol-Modifier C6-CE monomer, silver nitrate oxidation must be performed to remove the protecting group (trityl), while Thiol-Modifier C6 SS CE monomer must be modified with DTT to reduce the disulfide bond to the thiol.

[0188] Spacer modification: Spacer can provide the necessary spacer for oligonucleotide labeling to reduce the interaction between the labeling group and the oligonucleotide, and is mainly used in the study of DNA hairpin structure and double-stranded structure. C3 spacer is mainly used to mimic the three-carbon spacer between the 3' and 5' hydroxyl groups of ribose, or to "replace" an unknown base in a sequence. 3'-Spacer C3 is used to introduce a 3' spacer to prevent the 3' end exonuclease and 3' end polymerase from functioning. Spacer 18 is often used to introduce a strong hydrophilic group.

[0189] Thio-modification: Thio-modified oligonucleotides are mainly used in antisense experiments to prevent degradation by nucleases. You can choose all-thio, but as the number of thio bases increases, the Tm value of the oligonucleotide will decrease. In order to reduce this effect, 2-5 bases at both ends of the primer can be thio-modified. Usually, 3 bases at 5' and 3' can be selected for thio modification.

[0190] Deoxyuracil modification: Deoxyuracil can be inserted into oligonucleotides to increase the melting point of the duplex and thus increase the stability of the duplex. Each deoxythymine replaced by deoxyuracil can increase the melting point of the duplex by 1.7°C.

[0191] Deoxyhypoxanthine modification: Deoxyhypoxanthine is a naturally occurring base. Although it is not a universal base in the true sense, when combined with other bases, it is relatively more stable than other base mismatches. The binding ability of deoxyhypoxanthine with other bases is dI:dC>dI:dA>dI:dG>dI:dT. Under the catalysis of DNA polymerase, deoxyhypoxanthine prefers to bind to dC.

[0192] cfDNA

[0193] Circulating free DNA (cfDNA), also known as "liquid biopsy", avoids the need for tumor tissue biopsy and is a very useful diagnostic application in clinical practice. The use of liquid biopsy provides the possibility of repeated blood sampling, allowing the tracking of changes in cfDNA during tumorigenesis or cancer treatment, and then monitoring changes in the disease (Cell-free nucleic acids as biomarkers in cancer patients). However, there are currently huge technical challenges in the use of cfDNA testing to accurately and specifically detect gene mutations. First, the content of cfDNA in the blood varies from person to person, and in most cases it is very low, and the quality of tumor-derived free nucleic acids (circulating tumorDNA, referred to as "ctDNA") is even more uneven and the content varies. Not only that, the specificity of cfDNA detection methods needs to be improved. Douillard et al reported that the consistency between the detection of EGFR mutations in plasma and the detection results of tumor tissue was only 65%.

[0194] The main advantages of the present invention include:

[0195] 1. High sensitivity: Since this method uses a digital PCR platform, it can divide the reaction system into about 20,000 micro-reactions, and can theoretically detect single copy mutations, which has a sensitivity advantage that other technologies cannot match. The detection method of the present invention has been verified to achieve a minimum detection limit of 0.06%.

[0196] 2. Strong specificity: The designed specific primers are respectively targeted at the sequences of PIK3CA gene E545, E542 and PIK3CA gene H1047, and can specifically amplify the wild-type and mutant templates at the target position; the designed specific probes cover the mutation sites, and are designed for the wild type (2 in total) and mutant types (3 in total) of PIK3CA. The 5' end of the wild-type probe is modified with a HEX fluorescent group, and the 5' end of the mutant probe is modified with a FAM group. At the same time, the PIK3CA probe has a locked nucleic acid (LNA) modification at the mutant base, which greatly enhances the binding force of the nucleotide here. The PIK3CA probe has BHQ1 at the 3' end, which can effectively distinguish templates with a one-base difference. The design of the above primers and probes greatly improves the specificity of the detection.

[0197] 3. The requirements for sample type and quality are loose, and the anti-interference ability is strong. Due to its high sensitivity, the sample types applicable to the present invention include not only fresh tissue samples and paraffin sections commonly used in general methods, but also peripheral blood samples (this sample is easier to obtain, but the DNA content is low and broken); and due to the uniqueness of its digital PCR platform, the reaction system can be divided into about 20,000 small systems, and the interfering substances can also be divided into about 20,000 parts, which can greatly reduce the impact of interfering substances on the reaction, and of course, it can also detect samples with more complex backgrounds. This is something that other platforms cannot do.

[0198] 4. The positive judgment method is simple: Since the present invention adopts an absolute quantitative method, there is no need to set a control standard curve. The result can be determined based on the two-dimensional fluorescence graph to determine whether the target mutation template is contained (Table 1).

[0199] Table 1. Test results

[0200]

[0201] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods for which specific conditions are not specified in the following examples are usually performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are weight percentages and weight parts.

[0202] Unless otherwise specified, the materials and reagents used in the examples of the present invention are commercially available products.

[0203] Sequences of primers, probes, and amplicon fragments

[0204] In the examples, the nucleic acid sequence information of the primers, probes and amplified DNA fragments used are shown in Table 2:

[0205] Table 2: Nucleic acid sequences of primers, probes and DNA fragments

[0206]

[0207]

[0208] Example 1 Screening of primer pairs

[0209] According to the sequence of exon 9 of PIK3CA (sites E545 and E542), 5 pairs of primers were designed (primers were synthesized by Shanghai Sangon Biotechnology Co., Ltd.). The specific sequences are shown in Table 3 below.

[0210] Table 3. Screening of 5 primer pairs for amplification of PIK3CA E545 and E542

[0211]

[0212]

[0213] According to the PIK3CA exon 20 sequence (H1047 site), 5 pairs of primers were designed (primers were synthesized by Shanghai Sangon Biotechnology Co., Ltd.), and the specific sequences are shown in Table 4 below.

[0214] Table 4. Screening of 5 primer pairs for amplification of PIK3CA H1047

[0215]

[0216] Screening PCR system: Taq HS polymerase 0.2ul, 10×HS PCR buffer 2ul, dNTP mixture 1.6ul, upstream primer 1ul, downstream primer 1ul, tgDNA (human leukocyte genomic DNA, as template) 5ul, water to make up the system to 20ul.

[0217] Screening PCR program: 95°C for 10 min, 30 cycles (94°C for 30 s, 55°C for 30 s, 72°C for 20 s).

[0218] After PCR screening, E545, E542 primer pair 2 (E545 / E542-F2 and E545 / E542-R2) and H1047 primer pair 2 (H1047-F2 / H1047-R2) have high amplification efficiency (bright bands) for the target fragment, short amplification products, and no primer dimers are produced. They have the best overall effect and can be used as primer pairs for PIK3CA gene mutation detection. Figure 1 and Figure 2 .

[0219] Example 2 Optimization of Taqman probe and digital PCR reaction procedure

[0220] In this example, a Taqman probe was synthesized and optimized, and the digital PCR reaction program was optimized based on the optimized Taqman probe.

[0221] 2.1 Taqman Probes

[0222] In this example, the detected PIK3CA gene mutations are nucleotide mutations corresponding to E545K, E542K, and H1047R (Table 5);

[0223] Table 5: PIK3CA gene mutation information

[0224] Detection site Mutation type COSMIC Number Genetic changes E545K Point mutation COSM763 c.1633G>A E542K Point mutation COSM760 c.1624G>A H1047R Point mutation COSM775 c.3140A>G

[0225] Based on the genome sequence and mutation site of human PIK3CA, the corresponding Taqman probes were designed and optimized. The optimized Taqman probes contained specific locked nucleotides (+N), namely WTP-E545 / MTP-E545K, WTP-E542 / MTP-E542K, and WTP-H1047 / MTP-H1047R. The specific information of the probes is shown in Table 2.

[0226] 2.2 Optimization of digital PCR reaction program

[0227] Based on the optimal primer pairs determined in Example 1 (SEQ ID No: 1 and 2; SEQ ID No: 7 and 8) and the optimized probes determined in Example 2.1, the digital PCR reaction program is further optimized. The digital PCR reaction program optimization experiment requires a comprehensive analysis of the digital PCR amplification of the wild-type template and the mutant template as the annealing temperature changes. The optimal annealing temperature should meet two conditions: the negative control (wild-type template) has a clean background (no droplets in the FAM channel), and the positive and negative signals in the mutant template are easy to distinguish (high fluorescence intensity in the FAM channel and the HEX channel).

[0228] The experimental method is as follows:

[0229] Prepare the following PCR system in the reagent preparation area: 2×ddPCR Supermix (No dUTP) 11ul, upstream primer (E545 / E542-F or H1047-F) 1.1ul, downstream primer (E545 / E542-R or H1047-R) 1.1ul, probe 1 (WTP-E545, WTP-E542 or WTP-H1047) 0.55ul, probe 2 (MTP-E545K, or MTP-H1047R) 0.55ul, template 5.5ul, and make up to 22ul with water.

[0230] Add templates to the sample preparation area in the following order: negative control, positive control. The negative control is normal human leukocyte genome (tgDNA), and the positive control is a genomic DNA solution containing the corresponding mutation sequence of PIK3CA.

[0231] In the droplet generation area, droplet generation is performed according to instrument requirements.

[0232] In the sample analysis area, PCR reactions are performed and analyzed.

[0233] The PCR program of the ddPCR optimization experiment was as follows: 95°C for 10 min, 40 cycles {94°C for 30 s, annealing temperature gradient (60°C, 58°C, 56°C, 54°C) for 15 s, 72°C for 15 s}, 98°C for 10 min, and a heating and cooling rate of 2°C / s.

[0234] After completing PCR, set up the instrument according to the experimental requirements, select the FAM / HEX detection channel, and start reading the plate.

[0235] Results Figure 3 to Figure 5 Among them, the FAM channel indicates the droplets of mutant template detected by MTP probe and its fluorescence intensity (Amplitude), and the HEX channel indicates the droplets of wild-type template detected by WTP probe and its fluorescence intensity (Amplitude). FAM-HEX double-positive droplets represent the presence of both wild-type template and mutant template. The number of droplets in the FAM channel can be used to infer whether there is a mutant template in the digital PCR system and accurately calculate the copy number (copies / ul).

[0236] Figure 3 to Figure 5 The results showed that annealing at 56°C for 15 seconds resulted in no contamination in the digital PCR negative control, the most obvious distinction between negative and positive signals, and a better overall effect, which was the optimal annealing temperature.

[0237] Example 3: Sensitivity verification of digital PCR for detecting PIK3CA gene mutations

[0238] The wild-type template copy number (copies / ul), mutant template genome copy number (copies / ul) and mutation rate (%) were calculated according to Example 1, and both were diluted to 4000 copies / ul with TE. TgDNA was added to the mutant genome template so that the mutant template ratio was 0.06%, 0.13%, 0.25%, 0.5%, and 1%, respectively, to prepare a gradient dilution template.

[0239] Verify the digital PCR system: 2×ddPCR Supermix (No dUTP) 11ul, primer 1 (E545 / E542-F, H1047-F) 1.1ul, primer 2 (E545 / E542-R, H1047-R) 1.1ul, probe 1 (WTP-E545, E542 / WTP-H1047) 0.55ul, probe 2 (MTP-E545K, MTP-E545K, MTP-H1047R) 0.55ul, template 5.5ul, add water to make up to 22ul.

[0240] Templates were added to the sample preparation area in the following order: blank control, negative control, gradient dilution template. The blank control was water, the negative control was tgDNA, and the gradient dilution template was a wild-type template spiked with 0.06%-1% mutant template.

[0241] The PCR reaction system was generated into droplets in the same manner as in Example 1. PCR was performed according to the optimized PCR program: 95°C for 10 min, 40 cycles (94°C for 30 s, 56°C for 15 s, 72°C for 15 s), 98°C for 10 min, and the heating and cooling rate was 2°C / s. Plate reading was started according to the instrument requirements.

[0242] Digital PCR results Figure 6 to Figure 8 As shown. The digital PCR method of the present invention uses water or tgDNA as a template, and the background is clean and pollution-free. In addition, the digital PCR method of the present invention adds 0.06%-1% mutant template to the wild-type template, and the number of wild-type template copies detected is normal, and the proportion of mutant templates detected (mutant template divided by total template multiplied by 100%) is consistent with the theoretical proportion and is linearly correlated, R 2 The value is greater than 0.98. That is, the detection value of the digital PCR method of the present invention is accurate within the sensitivity range of 0.06%-1%, that is, the minimum detection sensitivity of the digital PCR method of the present invention is 0.06%.

[0243] Example 4: Digital PCR to detect PIK3CA mutations in patients and guide the use of tumor-targeted drugs

[0244] Cases "MS1106", "MS1124", "MS1133" and "MS1127" are all leukemia patients. Venous blood was collected, and plasma was separated by two centrifugations. The plasma free nucleic acid was extracted using a free nucleic acid extraction kit. The extracted nucleic acid was quantified by Qubit. After quantification, it was stored in a -20℃ refrigerator in the sample preparation room.

[0245] The digital PCR detection system of the present invention is shown in Example 2.

[0246] Templates were added to the sample preparation area in the following order: blank control, negative control, case free nucleic acid, positive control (1%).

[0247] The PCR reaction system was generated into droplets in the same manner as in Example 1. PCR was performed according to the optimized PCR program: 95°C for 10 min, 40 cycles (94°C for 30 s, 56°C for 15 s, 72°C for 15 s), 98°C for 10 min, and a heating and cooling rate of 2°C / s. Turn on the instrument, set it up as required, and start reading the plate. The blank control and negative control backgrounds of this PIK3CA test were clean, and the positive control copy number and mutation ratio were normal.

[0248] The results of nucleic acid sample testing of cases are shown in Table 6 below.

[0249] MS1106 was negative (see Fig. 9 ), does not contain E545K mutation, E542 mutation and H1047R mutation, and other gene mutations can be detected in the future to provide guidance on medication.

[0250] MS1124 was interpreted as E545K positive (see Fig.10 ; mutation rate is 0.743%), and targeted drugs such as gefitinib, erlotinib, and icotinib are not recommended for treatment;

[0251] Case MS1133 was interpreted as E542K positive (see Fig.11 ; mutation rate is 0.827%), and targeted drugs such as gefitinib, erlotinib, and icotinib are not recommended for treatment;

[0252] Case MS1127 was interpreted as H1047R positive (see Fig.12 ; mutation rate is 0.398%), and targeted drugs such as gefitinib, erlotinib, and icotinib are not recommended for treatment. The specific test data of the four cases are shown in the table below.

[0253] The specific test data of the above cases are shown in Table 6 below:

[0254] Table 6: Gene mutation results of case detection

[0255]

[0256] discuss:

[0257] Currently, the main methods for detecting gene mutations are:

[0258] (1) High-resolution melting curve (HRM). HRM is a gene analysis technology that forms different melting curves based on the different melting temperatures of single nucleotides. The detection sensitivity is around 1-10%. However, due to the high false positive rate of the dye method, sequencing verification is required later, resulting in a longer detection cycle.

[0259] (2) Probe amplification retardation mutagenesis (ARMS-qPCR). The principle that the 3'-terminal base of the PCR primer must be complementary to its template DNA for effective amplification is used to distinguish templates with certain point mutations from normal templates. The sensitivity of this detection method is higher than HRM, about 1% (CN104099422A). (3) Allele-specific Taqman polymerase chain reaction (CAST-PCR). CAST-PCR uses a specially designed MGB probe to prevent the primer from binding to wild-type DNA, selectively and preferentially amplifying mutant DNA. The sensitivity of this detection method is about 0.1%-1%. (Patent No. CN104099422A)Barbano R. et al used CAST-PCR technology to detect V600E and V600K mutations of the BRAF gene in clinical samples, and the sensitivity of their method was 1% (Competitive allele-specific TaqMan PCR (Cast-PCR) is a sensitive, specific and fast method for BRAF V600 mutation detection in Melanoma patients).

[0260] In summary, most of the existing gene mutation detection technologies are dye-based or probe-based fluorescent quantitative PCR technologies, which have problems such as low sensitivity, low accuracy, and complex positive judgment methods. They also have high requirements for the type and quality of samples. For example, some methods require tissue samples, and some methods can process plasma / serum samples but require patients with stage III or IV tumors.

[0261] The present invention uses digital PCR technology to distribute a sample into tens of thousands of independent small droplets, each of which performs PCR amplification on the target molecule, and analyzes the fluorescence signal of each droplet after the amplification. Digital PCR has the advantages of high sensitivity, accurate quantification without the need for a standard curve, and simple operation.

[0262] The present invention develops a highly sensitive and specific digital PCR method for PIK3CA E545K, E542K, and H1047R mutations. Compared with the prior art HRM, Arms-qPCR, CAST-PCR, etc., the present invention uses Taqman probes and combines digital PCR to solve the problems of low sensitivity, poor specificity, high requirements for sample type and quality, and complex positive interpretation methods. It has been verified that the sensitivity of the method of the present invention can reach up to 0.06%, which can not only accurately detect tissue and body fluid samples, but also process difficult samples such as plasma / serum.

[0263] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application. Sequence Listing <110> Mingchi Biotechnology (Shanghai) Co., Ltd. Mingshi Medical Technology (Ningbo) Co., Ltd. <120> Digital PCR detection method and application of human PIK3CA gene mutation <130> P2020-0094 <160> 31 <170> SIPOSequenceListing 1.0 <210> 1 <211> twenty two <212> DNA <213> Artificial sequence <400> 1 atgacaaaga acagctcaaa gc 22 <210> 2 <211> twenty two <212> DNA <213> Artificial sequence <400> 2 gcacttacct gtgactccat ag 22 <210> 3 <211> 15 <212> DNA <213> Artificial sequence <400> 3 tctcctgctc agtga 15 <210> 4 <211> 15 <212> DNA <213> Artificial sequence <400> 4 tctcctgctt agtga 15 <210> 5 <211> 18 <212> DNA <213> Artificial sequence <400> 5 cgagatcctc tctctgaa 18 <210> 6 <211> 19 <212> DNA <213> Artificial sequence <400> 6 cgagatcctc tctctaaaa 19 <210> 7 <211> twenty two <212> DNA <213> Artificial sequence <400> 7 ttgtgtggaa gatccaatcc at 22 <210> 8 <211> 20 <212> DNA <213> Artificial sequence <400> 8 aactgagcaa gaggctttgg 20 <210> 9 <211> 17 <212> DNA <213> Artificial sequence <400> 9 caccatgatg tgcatca 17 <210> 10 <211> 16 <212> DNA <213> Artificial sequence <400> 10 caccatgacg tgcatc 16 <210> 11 <211> 96 <212> DNA <213> Homo sapiens <400> 11 atgacaaaga acagctcaaa gcaatttcta cacgagatcc tctctctgaa atcactgagc 60 aggagaaaga ttttctatgg agtcacaggt aagtgc 96 <210> 12 <211> 96 <212> DNA <213> Artificial sequence <400> 12 atgacaaaga acagctcaaa gcaatttcta cacgagatcc tctctctgaa atcactaagc 60 aggagaaaga ttttctatgg agtcacaggt aagtgc 96 <210> 13 <211> 96 <212> DNA <213> Artificial sequence <400> 13 atgacaaaga acagctcaaa gcaatttcta cacgagatcc tctctctaaa atcactgagc 60 aggagaaaga ttttctatgg agtcacaggt aagtgc 96 <210> 14 <211> 95 <212> DNA <213> Homo sapiens <400> 14 aactgagcaa gaggctttgg agtatttcat gaaacaaatg aatgatgcac atcatggtgg 60 ctggacaaca aaaatggatt ggatcttcca cacaa 95 <210> 15 <211> 95 <212> DNA <213> Artificial sequence <400> 15 aactgagcaa gaggctttgg agtatttcat gaaacaaatg aatgatgcac gtcatggtgg 60 ctggacaaca aaaatggatt ggatcttcca cacaa 95 <210> 16 <211> 22 <212> DNA <213> Artificial sequence <400> 16 atgacaaaga acagctcaaa gc 22 <210> 17 <211> twenty three <212> DNA <213> Artificial sequence <400> 17 acctgtgact ccatagaaaa tct 23 <210> 18 <211> twenty two <212> DNA <213> Artificial sequence <400> 18 atgacaaaga acagctcaaa gc 22 <210> 19 <211> twenty three <212> DNA <213> Artificial sequence <400> 19 ccattttagc acttacctgt gac 23 <210> 20 <211> twenty two <212> DNA <213> Artificial sequence <400> 20 atgacaaaga acagctcaaa gc 22 <210> twenty one <211> twenty three <212> DNA <213> Artificial sequence <400> twenty one ctccatttta gcacttacct gtg 23 <210> twenty two <211> twenty three <212> DNA <213> Artificial sequence <400> twenty two acagctcaaa gcaatttcta cac 23 <210> twenty three <211> twenty three <212> DNA <213> Artificial sequence <400> twenty three acctgtgact ccatagaaaa tct 23 <210> twenty four <211> twenty one <212> DNA <213> Artificial sequence <400> twenty four tgtgtggaag atccaatcca t 21 <210> 25 <211> 20 <212> DNA <213> Artificial sequence <400> 25 aactgagcaa gaggctttgg 20 <210> 26 <211> twenty four <212> DNA <213> Artificial sequence <400> 26 gcatgctgtt taattgtgtg gaag 24 <210> 27 <211> 20 <212> DNA <213> Artificial sequence <400> 27 aactgagcaa gaggctttgg 20 <210> 28 <211> twenty four <212> DNA <213> Artificial sequence <400> 28 aatgcatgct gtttaattgt gtgg 24 <210> 29 <211> 20 <212> DNA <213> Artificial sequence <400> 29 aactgagcaa gaggctttgg 20 <210> 30 <211> twenty one <212> DNA <213> Artificial sequence <400> 30 tgtgtggaag atccaatcca t 21 <210> 31 <211> twenty two <212> DNA <213> Artificial sequence <400> 31 aaaactgagc aagaggcttt gg 22

Claims

1. A reagent for detecting gene mutation, characterized in that: The reagent is selected from the group consisting of: (a) a first primer pair for detecting PIK3CA E545 and / or E542 mutations, wherein the first primer pair comprises primers shown in SEQ ID Nos: 1 and 2; and (b) a second primer pair for detecting PIK3CA H1047 mutation, wherein the second primer pair comprises primers shown in SEQ ID No: 7 and 8; Wherein, the reagent also includes: (a1) a first probe used in conjunction with the first primer pair, wherein the first probe is a combination of the following probes: a probe shown in SEQ ID No: 3, a probe shown in SEQ ID No: 4, a probe shown in SEQ ID No: 5, and a probe shown in SEQ ID No: 6; and (b1) A second probe used in combination with the second primer pair, wherein the second probe is a combination of the following probes: a probe shown in SEQ ID No: 9 and a probe shown in SEQ ID No:

10.

2. The reagent according to claim 1, characterized in that The structure 5'-3' of the first probe is shown in Formula I: Z1-Z2-Z3 I in, Z1 is a fluorescent group; Z2 is a specific complementary nucleic acid sequence; Z3 is a quenching group; "-" is a chemical bond, a linker, or a linker consisting of 1-3 nucleotides.

3. The reagent according to claim 2, characterized in that The target site of the specific complementary nucleic acid sequence is selected from the following group: wild-type PIK3CA E545, E542 site, mutant PIK3CA E545K site, mutant PIK3CA E542K site.

4. The reagent according to claim 2, characterized in that The sequence of the specific complementary nucleic acid is selected from the following group: TCTCCTGCTCAGTGA, SEQ ID No: 3; TCTCCTGCTTAGTGA, SEQ ID No: 4; CGAGATCCTCTCTCTgAA, SEQ ID No: 5; CGAGATCCTCTCTCTAaaa, SEQ ID No:

6.

5. The reagent according to claim 2, characterized in that The fluorescent group is selected from the following group: FAM, VIC, HEX, FITC, BODIPY-FL, G-Dye100, FluorX, Cy3, Cy5, Texas Red, or a combination thereof.

6. The reagent according to claim 2, characterized in that The quenching group is selected from the group consisting of DABCYL, TAMRA, BHQ1, BHQ 2, BHQ3, MGB, NFQ, BBQ-650, TQ1-TQ6, QSY 7carboxylic acid, TQ7, eclipse, or a combination thereof.

7. The reagent according to claim 1, characterized in that The structure 5'-3' of the second probe is shown in Formula II: Z1'-Z2'-Z3'II in, Z1' is a fluorescent group; Z2' is a specific complementary nucleic acid sequence; Z3' is a quenching group; "-" is a chemical bond, a linker, or a linker consisting of 1-3 nucleotides.

8. The reagent according to claim 7, characterized in that The target site of the specific complementary nucleic acid sequence is selected from the following group: wild-type PIK3CA H1047 site and mutant PIK3CA H1047R site.

9. The reagent according to claim 7, characterized in that The sequence of the specific complementary nucleic acid is selected from the following group: CACCATGATGTGCATCA, SEQ ID No:9; CACCATGACGTGCATC, SEQ ID No:

10.

10. A kit, characterized in that: The kit contains the reagent for detecting gene mutation according to claim 1.

11. Use of the reagent for detecting gene mutation according to claim 1 or the kit according to claim 10, characterized in that: Used to prepare a diagnostic product, the diagnostic product is used to judge whether a subject is suitable for treatment with an EGFR targeted drug, or to pre-evaluate the effect of an EGFR targeted drug on a subject; Wherein, the EGFR targeted drug is selected from the following group: gefitinib, erlotinib, icotinib, cetuximab, panitumumab, or a combination thereof.

12. The use according to claim 11, characterized in that The subject is an EGFR-positive tumor patient, and the tumor patient includes a leukemia patient.

13. The use according to claim 11, characterized in that The EGFR targeted drug is selected from the group consisting of erlotinib, icotinib, cetuximab, panitumumab, or a combination thereof.

14. An in vitro non-diagnostic method for detecting whether a sample contains a gene mutation, characterized in that: Includes steps: (S1) providing a PCR reaction system, wherein the PCR reaction system contains a sample to be tested as a template and a primer pair for amplification, wherein the primer pair is selected from the following group: (a) a first primer pair for detecting PIK3CA E545 and / or E542 mutations, wherein the first primer pair comprises primers shown in SEQ ID Nos: 1 and 2; and (b) a second primer pair for detecting PIK3CA H1047 mutation, wherein the second primer pair comprises primers shown in SEQ ID No: 7 and 8; Wherein, the reaction system further comprises: (a1) a first probe used in conjunction with the first primer pair, wherein the first probe comprises: a probe shown in SEQ ID No: 3, a probe shown in SEQ ID No: 4, a probe shown in SEQ ID No: 5, and a probe shown in SEQ ID No: 6; and (b1) a second probe used in conjunction with the second primer pair, wherein the second probe comprises: a probe shown in SEQ ID No: 9 and a probe shown in SEQ ID No: 10; (S2) performing a PCR reaction on the PCR reaction system of step (S1) to obtain an amplified product; (S3) Analyzing the amplification product produced in step (S2) to obtain an analysis result of whether the sample to be tested contains a gene mutation.

15. The method according to claim 14, characterized in that The detection accuracy of the method is 0.06%-1%.

16. The method according to claim 14, characterized in that The detection accuracy of the method is 0.0625%-0.08%.

Citation Information

Patent Citations

  • Composition for detecting colorectal cancer hotspot gene mutation sites and using method of composition

    CN104099422A

  • Method of determining PIK3ca mutational status in a sample

    CA2957396A1

  • PIK3CA gene mutation detection probe, detection liquid phase chip and detection method thereof

    CN101445832A

  • Reagent kit used for testing PIK3CA (phosphatidylinositol-4,5-bisphosphate3-kinase, catalytic subunit alpha) gene mutations

    CN104372102A

  • PIK3CA gene mutation detection reagent kit

    CN111334580A